On Thursday, in the course of current trade, Shares of PROS Holdings, Inc. (NYSE:PRO), climbed 3.28%, and is now trading at $23.96.
PROS, declared it will co-present with customers at Dreamforce 2015 to showcase its smart applications for pricing and selling built on the Salesforce1 platform. PROS cloud-based smart applications with predictive and prescriptive analytics provide Salesforce CRM customers with guidance to assist supercharge revenue and profits.
“PROS is redefining selling with our next-generation smart applications for the Salesforce community,” said PROS Chief Operating Officer Blair Crump. “The combination of pricing and selling solutions with predictive and prescriptive analytics provides PROS customers with a planned business advantage that extends the value of their Salesforce CRM investments. Together with our customers, we’ll share compelling stories of how PROS enables companies to outperform.”
PROS smart applications – counting solutions for configure-price-quote (CPQ), eCommerce, Deal Desk and Pricing – combine automation, analytics and intelligence.
PROS Holdings, Inc. provides big data software applications worldwide. It offers pricing and sales effectiveness software solutions that enable companies in the manufacturing, distribution, and services industries to analyze, optimize, and execute sales, pricing, quoting, and rebate strategies, such as Scientific Analytics, Price Optimizer, Deal Optimizer, Sales Optimizer, and Cameleon configure-price-quote.
During an Afternoon trade, Shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI), climbed 0.95%, and is now trading at $14.89.
Karyopharm Therapeutics, stated that its SINE(TM) nuclear transport compounds are being evaluated for the treatment of Amyotrophic Lateral Sclerosis (ALS) and that preclinical data abstracts will be presented at two forthcoming neuroscience meetings. A recent publication appearing in the journal Nature confirmed that nuclear transport is disrupted in a common mutation found in ALS. Given the tremendous unmet need for new treatments for ALS, Karyopharm is advancing its oral SINE(TM) compound KPT-350 for this indication. While Karyopharm’s primary clinical focus is in advancing its lead SINE(TM) compound oral selinexor for human cancer, other SINE(TM) compounds have already shown beneficial pharmacological effects in several neurodegenerative and anti-inflammatory preclinical models, counting multiple sclerosis, systemic lupus and traumatic brain injury.
The Nature publication entitled “The C9orf72 repeat expansion disrupts nucleocytoplasmic transport” stated that C9orf72, the most common cause of familial and sporadic ALS and Frontotemporal Degeneration, results in problems with nuclear protein trafficking that affect neural function and survival. The mutation causes the affected cells to create long strands of repeating RNA, thus blocking critical pathways for nuclear transport of proteins. A first set of experiments using a fruit fly model of human ALS to screen for candidates that block brain cell death in a living organism identified a protein RanGAP, a key regulator of nucleocytoplasmic transport, that acts as a potent suppressor of neurodegeneration. Compriseent with the interaction of RanGAP with XPO1 (exportin 1), the studies further showed that suppressing nuclear export of proteins also suppresses neurodegeneration. The results were validated in human stem cell derived motor neurons and autopsied brains.
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.
Shares of Mellanox Technologies, Ltd. (NASDAQ:MLNX), climbed 0.42%, and is now trading at $42.66.
Mellanox Technologies, declared that it has been honored with the 2015 Israel - America Chamber of Commerce award in recognition of the company for “innovation and technology excellence, and developing human capital.”
Since its inception in 1999, Mellanox has collaborated with a long list of U.S. governmental organizations and agencies, leading server, storage, data center, Web 2.0 and cloud companies, and has assisted to build a great relationship between Israel and the U.S.
“We are honored to receive this award by the Israel - America Chamber of Commerce, one of the major bodies connecting and bridging between Israeli and American companies. Mellanox, and the thousands of Israeli startups and companies, have turned Israel into a highly advanced technology hub, which heavily rely on the cooperation with U.S. companies,” said Eyal Waldman, CEO and president of Mellanox. “Mellanox serves the largest U.S.-based server and storage providers with our high-performance Ethernet and InfiniBand interconnect solutions, and we continue to grow and expand our activities in the high-performance computing, Cloud, Web 2.0, financial, Big Data, enterprise data center and other markets.”
Mellanox Technologies, Ltd., a fabless semiconductor company, designs, manufactures, and sells interconnect products and solutions. The company’s products are used for computing, storage, and communications applications in the high-performance computing, Web 2.0, storage, financial services, enterprise data center, and cloud markets.
Finally, Lennox International Inc. (NYSE:LII), lost -0.01% Thursday.
Lennox International, declared that Chairman and CEO Todd Bluedorn presented at the Morgan Stanley 3rd Annual Laguna Conference on Wednesday, September 16.
Lennox International Inc. is a global leader in the heating, air conditioning, and refrigeration markets. Lennox International stock is listed on the New York Stock Exchange and traded under the symbol “LII”.
Lennox International Inc., through its auxiliaries, designs, manufactures, and markets climate control products for the heating, ventilation, air conditioning, and refrigeration markets. The company operates in three segments: Residential Heating & Cooling, Commercial Heating & Cooling, and Refrigeration.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
